Lymphocyte Transfer Factors: Between Evidence and Controversy
Between Immune Potential and Lack of Evidence
Leukocyte transfer factors (LTFs) have been proposed as immune-modulating agents, but their use remains controversial. Despite their clinical application in countries like Cuba, the lack of solid clinical evidence, unclear mechanisms of action, and poor regulatory oversight hinder their acceptance. This article reviews their origin, current use, associated risks, and the standards needed to validate their therapeutic potential. The message encourages a critical and responsible perspective on such therapies. Readers are invited to consult Baja Regenerative Medical Center for professional guidance and more information regarding safe and evidence-based immunomodulatory alternatives.
Leukocyte transfer factors (LTFs), also known as transfer factors (TF) or dialyzable leukocyte extracts, are products derived from leukocytes intended to modulate the immune system. Their function is to transfer immune information from a donor to a recipient to stimulate the immune response. Although the concept has drawn attention for decades, its use remains controversial.
The concept was first introduced in 1955 by Dr. H. Sherwood Lawrence, who observed that it was possible to transfer cellular immunity to a non-sensitized individual through extracts obtained from human leukocytes. From that point on, the idea emerged that certain intracellular components could contain “immune memory” capable of inducing a specific immune response in a new host. These extracts, later known as dialyzable leukocyte extracts, became the subject of multiple exploratory studies during the 1960s and 1970s for chronic infections, autoimmune diseases, and certain cancers. However, their formal development as therapeutic agents was limited by lack of standardization and insufficient clinical evidence.
Clinical Use and Controversy
The main obstacle to the formal acceptance of LTFs is the lack of robust clinical data. There are reports of improvement in small groups of volunteers, but also cases where no positive effects are observed. This ambiguity has generated conflicting opinions about their therapeutic use.
Possible reasons for this variability include individual differences in immune response, the quality of the extract used, baseline clinical conditions, and the absence of standardized administration protocols. Additionally, the lack of precise molecular characterization of the active components hampers reproducibility and effectiveness across batches and manufacturers.
Regarding composition, it has been proposed that the immune transfer activity comes from low molecular weight peptides (under 10 kDa), some possibly associated with RNA fragments. However, no single molecule has been conclusively identified as responsible for the immunomodulatory effect. This lack of precision remains a major barrier to standardization and scientific validation.
Cuba has been a pioneer in the therapeutic use of LTFs, particularly through the Center for Genetic Engineering and Biotechnology (Hebertrans®), which has developed and distributed related products for over 20 years.
In 2019, Cruz Barrios conducted a review of clinical trials involving Hebertrans®. While the reports claimed effectiveness, adverse reactions were not systematically recorded. Only through subsequent pharmacovigilance were both benefits and side effects documented.
Quality, Regulation and Risks
One of the most critical issues is the reliability of reported data. Many studies fail to clearly define success criteria and do not control for external variables such as concurrent medications, diet, or complementary therapies.
Moreover, the commercial boom has led to the emergence of numerous unregulated products. Guidos Folgelbachi (2016) analyzed LTFs produced by various companies including Inmunoactive®, Terrat®, Transferon®, Celestine®, and G-nomic®, many of which do not meet recognized quality control standards or regulatory frameworks.
To ensure quality, effective regulation, and minimize risks associated with LTF use, it would be necessary to establish clear regulatory frameworks outlining minimum standards for production, biological validation, and clinical monitoring. This should include mandatory good manufacturing practices (GMP), multicenter controlled studies, and active pharmacovigilance protocols. Additionally, more investment is needed in basic research to identify and characterize the bioactive components responsible for therapeutic effects.
Conclusions
Leukocyte transfer factors represent an immunomodulatory strategy that has sparked both scientific interest and informal clinical use across different countries. Their therapeutic potential remains a topic of exploration, yet progress is hindered by a lack of solid evidence, clinical variability, and uncontrolled production.
To validate their role in immunotherapy, it is essential to adopt rigorous quality standards, well-defined clinical evaluation protocols, and dedicated research to understand their molecular mechanisms. Only with a responsible and scientific approach can we determine whether LTFs are a promising tool or an unfounded therapeutic risk.
At Baja Regenerative Medical Center, we are committed to the critical analysis and responsible application of immunological therapies. If you would like more information or wish to learn about current immunomodulatory alternatives, please contact us for professional guidance.
References
- Cruz Barrios, M. A., & Furones Mourelle, J. A. (2019). Beneficio-riesgo del uso de factor de transferencia (Hebertrans®) en la práctica médica habitual. Horizonte Sanitario, 18(2), 1–9. https://doi.org/10.19136/hs.a18n2.2918SciELO+3SciELO+3SciELO+3
- González, M. A., & Rodríguez, L. J. (2004). Efectos del factor de transferencia en pacientes con inmunodeficiencia. Revista Cubana de Medicina, 43(3), 200–207. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892004000300006
- Guidos-Fogelbach GA, Paredes-Aguilar JA, Colín-Martínez NM, Rojo-Gutiérrez MI, López-Hidalgo M, Reyes-López CAS. Determinación y análisis del perfil proteico de diferentes factores de transferencia. Rev Alerg Mex. 2016;63(4):365-372. https://www.revistaalergia.mx/ojs/index.php/ram/article/view/190/383
